regenicin header

Regenicin™ to Present at the Rodman & Renshaw Healthcare Conference

regenicin news release

Regenicin™ to Present at the Rodman & Renshaw Healthcare Conference

NEW YORK, Sept. 8 /PRNewswire/ -- Regenicin™ (OTC Bulletin Board: WDST), a clinical-stage company developing next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin, will present at the Rodman & Renshaw Healthcare Conference held at the New York Palace Hotel, New York City from September 12-15, 2010.

Regenicin™ President Joe Connell will speak on Wednesday, September 15th at 11:15 am EDT to provide a status update on the company's Pipeline lead candidate PermaDerm™ as well as a general overview of Regenicin™, which went public in August.

About the Rodman Healthcare Conference
The Rodman & Renshaw Annual Global Investment Conference will be held at the New York Palace Hotel September 12th-15th. Henry M. Paulson, Jr., 74th United States Secretary of the Treasury (2006-2009), will open the conference as the keynote speaker on Monday, September 13, 2010 in a moderated interview hosted by Lawrence Kudlow, renowned free market, supply-side economist and host of CNBC's The Kudlow Report. William Isaac, former Chairman of the Federal Deposit Insurance Corporation and author of the 2010 book Senseless Panic: How Washington Failed America, will also be a special guest speaker at the conference on Tuesday, September 14th, 2010 at 5:30 PM.

Following Mr. Paulson's opening program, more than 200 public and private companies from around the world are expected to present to an audience of over 3,500 attendees.

return to 2010 Press and News Releases
return to Home Page

About Regenicin
Regenicin, Inc. (OTC Bulletin Board: RGIN), is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Regenicin, which was founded in 2010, has assembled a world-class management team with a proven track record for developing and bringing innovative medical devices and biotechnology products to market. The company is publicly traded with headquarters in New Jersey.

Safe Harbor Statement.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: Regenicin, Inc.